Biomarker Research,
Год журнала:
2023,
Номер
11(1)
Опубликована: Дек. 1, 2023
Adoptive
cell
therapy
using
T
receptor-engineered
cells
(TCR-T)
is
a
promising
approach
for
cancer
with
an
expectation
of
no
significant
side
effects.
In
the
human
body,
mature
are
armed
incredible
diversity
receptors
(TCRs)
that
theoretically
react
to
variety
random
mutations
generated
by
tumor
cells.
The
outcomes,
however,
current
clinical
trials
TCR-T
therapies
not
very
successful
especially
involving
solid
tumors.
still
faces
numerous
challenges
in
efficient
screening
tumor-specific
antigens
and
their
cognate
TCRs.
this
review,
we
first
introduce
TCR
structure-based
antigen
recognition
signaling,
then
describe
recent
advances
neoantigens
specific
technologies,
finally
summarize
ongoing
against
neoantigens.
More
importantly,
also
present
cell-based
immunotherapies,
e.g.,
safety
viral
vectors,
mismatch
receptor,
impediment
suppressive
microenvironment.
Finally,
highlight
new
insights
directions
personalized
therapy.
Journal of Chemical Theory and Computation,
Год журнала:
2023,
Номер
19(16), С. 5315 - 5333
Опубликована: Авг. 1, 2023
The
design
of
new
biomolecules
able
to
harness
immune
mechanisms
for
the
treatment
diseases
is
a
prime
challenge
computational
and
simulative
approaches.
For
instance,
in
recent
years,
antibodies
have
emerged
as
an
important
class
therapeutics
against
spectrum
pathologies.
In
cancer,
immune-inspired
approaches
are
witnessing
surge
thanks
better
understanding
tumor-associated
antigens
their
engagement
or
evasion
from
human
system.
Here,
we
provide
summary
main
state-of-the-art
that
used
antigens,
parallel,
review
key
methodologies
epitope
identification
both
B-
T-cell
mediated
responses.
A
special
focus
devoted
description
structure-
physics-based
models,
privileged
over
purely
sequence-based
We
discuss
implications
novel
methods
engineering
with
tailored
immunological
properties
possible
therapeutic
uses.
Finally,
highlight
extraordinary
challenges
opportunities
presented
by
integration
emerging
Artificial
Intelligence
technologies
prediction
epitopes,
antibodies.
Vaccines,
Год журнала:
2023,
Номер
11(3), С. 636 - 636
Опубликована: Март 13, 2023
mRNA
vaccines
encoding
tumor
antigens
may
be
able
to
sensitize
the
immune
system
of
host
against
cancer
cells,
enhancing
antigen
presentation
and
response.
Since
breakout
COVID19
pandemic,
interest
in
has
been
accelerating,
as
vaccination
virus
served
a
measure
limit
disease
spread.
Given
that
immunotherapy
cornerstone
melanoma
treatment
over
last
several
decades,
further
innate
immunity
enhancement
by
targeted
could
next
pivotal
achievement
treatment.
Preclinical
data
coming
from
murine
models
have
already
provided
evidence
vaccines'
ability
induce
responses
cancer.
Moreover,
specific
observed
patients
receiving
vaccines,
while
recent
KEYNOTE-942
trial
establish
incorporation
mRNA-4157/V940
vaccine
into
algorithm,
combination
with
checkpoint
inhibition.
As
existing
are
tested
reviewed,
investigators
gaining
enthusiasm
about
this
novel,
promising
pathway
therapy.
Recent
advances
in
neoantigen
research
have
accelerated
the
development
of
tumor
immunotherapies,
including
adoptive
cell
therapies
(ACTs),
cancer
vaccines
and
antibody-based
therapies,
particularly
for
solid
tumors.
With
next-generation
sequencing
bioinformatics
technology,
rapid
identification
prediction
tumor-specific
antigens
(TSAs)
has
become
possible.
Compared
with
tumor-associated
(TAAs),
highly
immunogenic
TSAs
provide
new
targets
personalized
immunotherapy
can
be
used
as
prospective
indicators
predicting
patient
survival,
prognosis,
immune
checkpoint
blockade
response.
Here,
characterization
neoantigens
clinical
application
neoantigen-based
TCR-T
strategies
are
summarized,
current
status,
inherent
challenges,
translational
potential
these
discussed.
Biomarker Research,
Год журнала:
2023,
Номер
11(1)
Опубликована: Дек. 1, 2023
Adoptive
cell
therapy
using
T
receptor-engineered
cells
(TCR-T)
is
a
promising
approach
for
cancer
with
an
expectation
of
no
significant
side
effects.
In
the
human
body,
mature
are
armed
incredible
diversity
receptors
(TCRs)
that
theoretically
react
to
variety
random
mutations
generated
by
tumor
cells.
The
outcomes,
however,
current
clinical
trials
TCR-T
therapies
not
very
successful
especially
involving
solid
tumors.
still
faces
numerous
challenges
in
efficient
screening
tumor-specific
antigens
and
their
cognate
TCRs.
this
review,
we
first
introduce
TCR
structure-based
antigen
recognition
signaling,
then
describe
recent
advances
neoantigens
specific
technologies,
finally
summarize
ongoing
against
neoantigens.
More
importantly,
also
present
cell-based
immunotherapies,
e.g.,
safety
viral
vectors,
mismatch
receptor,
impediment
suppressive
microenvironment.
Finally,
highlight
new
insights
directions
personalized
therapy.
